Seven arginylfluoroalkanes ('arginine fluoroalkyl ketones') were synthesized by using a modified Dakin-West procedure. inhibitor of human factor Xa or of Factor XIIa. The arginylfluoroalkanes were tested in the prothrombin time (PT) and activated partial thromboplastin time (APTT) coagulant assays. Two fluoroketones, benzoylArg-CF2CF3 and -naphthoyl-Arg-CF3, had significant anticoagulant activity. Benzoyl-Arg-CF2CF3 was found to prolong the PT 1.8-fold at 120,M and to prolong the APTT 2.4-fold at 90,UM, whereas l-naphthoyl-Arg-CF3 only prolonged the APTT 1.7-fold at 100 /LM.
INTRODUCTION
A large number of peptidylchloromethanes ('peptide chloromethyl ketones') have been described as irreversible inhibitors for serine proteinases [for reviews see Powers (1977) and Powers & Harper (1986) ]. In contrast, only a handful ofpeptidylfluoromethanes ('peptide fluoromethyl ketones') have been prepared as inhibitors for cysteine proteinases and serine proteinases. The first reported peptidylfluoromethane was the cathepsin B irreversible inhibitor Z-Phe-Ala-CH2F (Rasnick, 1985) . It alkylated cathepsin B more slowly (lower k3) than the corresponding chloromethyl ketone Z-Phe-Ala-CH2Cl, but was bound more tightly by the enzyme (lower K1). Subsequently, Z-Phe-CH2F was found to inactivate chymotrypsin with the formation of a covalent bond to the active-site histidine residue (Rauber et al., 1986) . However, the inhibition rate was much lower than with the chloromethyl ketone Tosyl-Phe-CH2Cl (Schoellmann & Shaw, 1962 , 1963 .
More highly fluorinated fluoroketones are potent transition-state inhibitors for serine proteinases and in most cases do not alkylate the enzyme. The inhibitors include Ac-Leu-ambo-Phe-CF3 for chymotrypsin, Ac-Ala-AlaPro-ambo-Ala-CF3 for pig pancreatic elastase (Imperiali & Abeles, 1986b) and Z-Lys(-Z)-Val-Pro-Val-CF3 for human leucocyte elastase (Stein et al., 1987; Dunlap et al., 1987) . Upon binding to the serine proteinase, several of the fluoroketone inhibitors have been shown to react with the hydroxy group of the active-site serine residue to form a hemiketal structure resembling the transition state for peptide-bond hydrolysis (Takahashi et al., 1988) .
Several monofluoromethyl ketone derivatives of lysine and arginine peptides, including Lys-Ala-Lys-CH2F (McMurray & Dyckes, 1986) , Bz-Phe-Lys-CH2F and Ala-Phe-Lys-CH2F (Angliker et al., 1987) , Bz-Phe-Arg-CH2F and D-Phe-Pro-Arg-CH2F (Angliker et al., 1988) , have been synthesized as inhibitors for trypsin and trypsin-like enzymes. The monofluoromethyl ketone derivatives of lysine peptides, like their corresponding chloromethyl ketones, were found to be active-sitedirected irreversible inhibitors of trypsin. In the present paper we report the syntheses of arginylpolyfluoroalkanes. These compounds are good reversible inhibitors for trypsin and several blood-coagulation serine proteinases. Two of the arginylfluoroalkanes also showed anticoagulant activity. (1939) , with some modification. The synthesis of ptoluoylarginine hydrochloride is described as an example. p-Toluoyl chloride (3.5 ml, 26 mmol) and Na2CO3 (5.11 g, 48 mmol) in water (50 ml) were added (one-fifth portion every 10 min) to a vigorously stirred mixture of diethyl ether and a solution of arginine hydrochloride (4.22 g, 20 mmol) in 25 ml of water. The reaction mixture was stirred for another 2.5 h, and excess acid chloride was removed by extraction with diethyl ether. The pH of the aqueous layer was adjusted to pH 2 with 50 (w/v) HCl and the precipitate was filtered. The filtrate was mixed with saturated NaCl, and the product was dissolved in ethyl acetate/2-methylpropan-2-ol (1: 1, v/v) (Kolb et al., 1986) , and the synthesis of BZ-DLArg-CF3 is described as an example. To a solution of benzoylarginine hydrochloride (1.40 g, 5 mmol) and 4-dimethylaminopyridine (37 mg, 0.3 mmol) in tetrahydrofuran was added trifluoroacetic anhydride (10.5 ml, 74 mmol) at 40°C under an N2 atmosphere. The reaction was continued under the same conditions for 5 h. The solvent was removed in vacuo, and the residual oil was purified by using a Chromatotron, with elution first with dichloromethane and then with dichloromethane/methanol (9:1, v/v). The 
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Kinetics measurements Z-Arg-SBzl was used as a substrate for trypsin and the coagulation serine proteinases (McRae et al., 1981) . The hydrolysis rates of Z-Arg-SBzl were measured in 0.01 MCaCl2/0.1 M-Hepes buffer, pH 7.5, containing 9 % (v/v) dimethyl sulphoxide and 0.34 mM-4,4'-dithiodipyridine at 25 'C. The rate was monitored by the increase in the absorbance at 324 nm (6324 19 800 mW' cm-' for 4-thiopyridone; Grassetti & Murray, 1967 ) with a Beckman 35 spectrophotometer when 25 pAl of enzyme solution (0.06-1.8 /M) was added to a cuvette containing 2 ml of buffer, 150,1 of 4,4'-dithiodipyridine, 25,l of substrate solution and 25,l of inhibitor solution. Initial-rate measurements were used with all enzymes except for trypsin, which shows a slow-binding type of inhibition. Therefore the steady-state rates were measured for trypsin by preincubation of trypsin with inhibitor for 5 min before addition of substrate and 4,4'-dithiodipyridine. (Nye et al., 1962) blood-coagulation assays were measured with an MLA Electra 750 coagulation timer. The PT was measured in the presence of inhibitor by incubating normal citrated human plasma (0.1 ml) with 0.02 ml of inhibitor solution at 37 'C for 3 min. Orthobrain thromboplastin (0.2 ml) was then added and the clotting time was determined. The APTT was measured by incubating citrated human plasma (0.1 ml) with 0.02 ml of inhibitor solution and 0.1 ml of activated Thrombofax reagent at 37 'C for 4 min, followed by the addition of 0.1 ml of 0.02 M-CaCl2 (preincubated at 37 'C), and the clotting time determined. Inhibitor stock solutions were prepared in dimethyl sulphoxide. For determination of PT and APTT the inhibitor solution was further diluted 10-fold with 0.5 M-NaCl/0.1 M-Hepes buffer, pH 7.5, and thus the dimethyl sulphoxide concentration was lowered to 10 % before addition to the assay system. No prolongation of the PT or APTT was observed at this dimethyl sulphoxide concentration.
RESULTS Synthesis
Several methods for the synthesis of a-fluoroalkyl ketones have been described in the literature. The Reformatsky reaction was used in the synthesis of difluorostatone-containing peptides, which are potent renin inhibitors (Thaisrivongs et al., 1985; Fearon et al., 1987) . Condensation ofnitroalkanes with the appropriate fluorinated aldehyde hydrate was used to prepare peptidylfluoromethanes as chymotrypsin and elastase inhibitors (Imperiali & Abeles, 1986a,b) . A modified Dakin-West method was also used to prepare Z-Phe-Ala-CH2F (Rasnick, 1985) and a-benzamidoalkyl mono-, di-and trifluoromethyl ketones (Kolb et al., 1986) .
Seven arginylfluoroalkanes were synthesized from the corresponding N-acylated arginine by using a convenient one-pot Dakin-West reaction. The N-acylated arginine hydrochloride salts (1 equiv.) were reacted with 15 equiv. of trifluoroacetic anhydride or various other fluorinated anhydrides and a catalytic amount of 4-dimethylaminopyridine at 40°C under N2 for 5 h. Under the conditions of the reaction, the anhydrides reacted with the various 2-phenyl-5(4H)-oxazolones generated in situ from the corresponding acylarginine derivatives to form keto acid intermediates. With amino acids having stable side chains, decarboxylation of the acylated oxazolone to the fluoroketone product is often accomplished by heating with anhydrous oxalic acid at 110-120°C for 10-15 min (Kolb et al., 1986) . To avoid possible side reactions of the arginyl fluoroalkanes at high temperature and avoid the necessity of removing the oxalic acid from the product, we utilized 4-dimethylaminopyridine to accomplish the decarboxylation during the reaction. With 4-dimethylaminopyridine the Dakin-West reaction can be accomplished at room temperature (Steglich & Hofle, 1969; Hofle et al., 1978 ; synthesis of Bz-Ala-CH2F, Rasnick, 1985) . The yields of the reaction varied from 8 % (Bz-DL-Arg-CF2CF2CF3) to 65 % (Bz-DL-ArgCF2Cl). The final products were purified by chromatography with a Chromatotron and are racemic at the arginine a-carbon atom owing to the formation of the intermediate oxazolone.
Structure
The structures of the arginyl fluoroalkanes were confirmed by m.s., the Sakaguchi reaction and 19F-n.m.r. spectra. The final products were single spots on t.l.c. and gave positive Sakaguchi reactions. The Sakaguchi reaction involves formation of a red colour upon treatment of an alkaline solution of a monosubstituted guanidine and a-naphthol with sodium hypobromite. Arginine, octopine, glycocyamine, z-guanidinobutyric acid and monomethylguanidine give positive reactions, whereas dimethylguanidine, nitroarginine, citrulline, creatinine, creatine, a4-dibenzoylarginine and canavanine are unreactive (Greenstein & Winitz, 1961; Sakaguchi, 1925) . Possible alternative structures for the Dakin-West reaction products include derivatives with acylated guanidino groups, ornithine derivatives (Rink et al., 1984) or citrulline derivatives; however, none of these would give positive Sakaguchi reactions.
The mass spectra of the fluoroalkyl ketones were consistent with their assigned structures. Most of the ketones, including Bz-Arg-CF2CF3, Bz-Arg-CF2CF2CF3, adamantanoyl-Arg-CF3, naphthoyl-Arg-CF3 and p-toluoyl-Arg-CF3, had peaks at M+ 1 and M+ 18+1 in the mass spectra. The latter corresponds to the hydrated form of the ketone. Since the f.a.b. mass spectra were measured in a thioglycerol matrix, there were often higher mass peaks corresponding to M+ 1 + 108 (thioglycerol) or fragments of this ion. However, there were no peaks corresponding to any of the alternative structures listed above.
The '9F-n.m.r. spectrum of Bz-Arg-CF2CF3,-CF3CF2CO2H had two peaks at -80.6 and -81.2 p.p.m. and another two peaks at -118.0 and -19.9 p.p.m. The peaks around -80 p.p.m. were assigned to the two CF3 groups of Bz-Arg-CF2CF3 and CF3CF2CO2H, and the peaks around -119 p.p.m. were assigned to the corresponding CF2 groups. The 19F-n.m.r. spectra of several substituted Bz-Phe-CF3 compounds have been reported (Kolb et al., 1986 (Maeda et al., 1971; Shimizu et al., 1972) . Similarly, the arginylfluoroalkanes could exist as cyclic carbinolamine species [(I) in Fig. 1 ], which can be easily formed from the keto form [(II) in Fig. 1 1990 0.4-trypsin, pig pancreatic elastase (Imperiali & Abeles, 1986b ) and human leucocyte elastase (Stein et al., 1987) .
Peptidyltrifluoromethanes are slow-binding inhibitors, Arg-CH2F and Bz-Phe-Arg-CH2F (Angliker et al., 1988) have been synthesized as inhibitors for trypsin-like Curve A, trypsin was added to the buffer solution conenzymes. These lysyl-and arginyl-monofluoromethanes taining Z-Arg-SBzl (75 /M) and 4,4'-dithiodipyridine irreversibly inactivated several enzymes, although the (0.34mM). The trypsin concentration was 0.6 nm. Curve B, inactivation rates are much lower than those of the trypsin was added to the buffer solution containing Z-Argcorresponding chloromethyl ketones. Lys-Ala-Lys-CH2F SBzl, 4,4'-dithiodipyridine and Bz-Arg-CF3 (54 ,LM). Curve had a K. value of 1 /tM for trypsin (McMurray & Dyckes, C, trypsin and Bz-Arg-CF3 were incubated at room 1986) and Ala-Phe-Lys-CH2F had a K. value of 5 ,uM for temperature for 5 min, then Z-Arg-SBzl and 4,4'-dithioplasmin (Angliker et al., 1987) The control value of PT is 11.1 s. The only compound For example, Bz-Phe-CF3 was only a competitive inthat has a significant effect is Bz-Arg-CF2CF3, which hibition of chymotrypsin, whereas Bz-Leu-Phe-CF3 was increases the PT 1.8-fold at 120 /M. This anticoagulant a slow-binding inhibitor (Imperiali & Abeles, 1986b (Sturzebecher et al., 1976 (Gelb et al., 1985) , chymobetter electron-withdrawing group compared with an Vol. 265 alkyl or chloromethyl group, this effect did not produce a lower K, in the thrombin case. The tripeptidyl inhibitor D-Phe-Pro-Arg-CH2F, which contains a thrombinspecific sequence, was a 50-fold better inhibitor than Bz-Arg-CF2CF3 (Angliker et al. 1988 ). The tripeptidylfluoromethane is much less potent than would be expected on the basis of results with the corresponding chloromethyl ketone. Interestingly, the arginylfluoroalkanes showed some selectivity towards various coagulation enzymes. BzArg-CF2CF3 is the best inhibitor for thrombin, plasma kallikrein and Factor XIa, but it did not inhibit pancreatic kallikrein or human Factor XIIa. Bz-Arg-CF3 inhibited pancreatic and plasma kallikreins effectively, but not the other coagulation enzymes. Both p-toluoyl-Arg-CF3 and Bz-Arg-CF2Cl only showed good inhibitory activity towards pancreatic kallikrein. It is apparent that the different acyl groups such as benzoyl, p-toluoyl, adamantanoyl and 1-naphthoyl on the a-amino group of the arginine residue and the various fluoroalkyl group moieties (trifluoromethyl, pentafluoro or heptafluoro) will affect the inhibitory behaviour towards the different coagulation enzymes. The potent thrombin inhibitor 4-methyl-I -[N2-(3-methyl-1,2,3,4-tetrahydroquinoline-8-sulphonyl)-L-arginyl]piperidine-2-carboxylic acid, an arginine derivative, was developed by gradual changes in the inhibitor structure on both the ac-amino blocking group and arginine amide group (Kikumoto et al., 1984) , and a similar strategy should succeed with arginylfluoroalkanes.
The arginylfluoroalkanes Bz-Arg-CF2CF3 and 1-naphthoyl-Arg-CF3 were moderately effective as anticoagulants. Bz-Arg-CF2CF3 doubled the PT and APTT at 90-120 /tM, and 1-naphthoyl-Arg-CF3 prolonged APTT approx. 1.7-fold at 100 ,uM. Since Bz-Arg-CF2CF3 inhibited thrombin, plasma kallikrein and Factor XIa, it was expected that this compound would inhibit clotting of both the intrinsic and the extrinsic pathways. Although 1-naphthoyl-Arg-CF3 was not a good inhibitor of any of the coagulation enzymes tested, it was an effective inhibitor of intrinsic-pathway coagulation. Several coagulation factors, such as Factor IXa in the intrinsic pathway and Factor VIIa in the extrinsic pathway, have not been tested with these fluoroalkyl ketones, and it is possible that they are effectively inhibited by several of the arginylfluoroalkanes. Until the inhibition of all the coagulation factors is checked with these compounds, it is difficult to explain their anticoagulant behaviour rationally.
The potent thrombin inhibitors (2R,4R)-4-methyl-1-[N2-(3-methyl-1,2,3,4-tetrahydroquinoline-8-sulphonyl)-L-arginyl]piperidine-2-carboxylic acid (Ki 0.02,M; Kikumoto et al., 1984) and naphthalene-2-sulphonylglycine 4-amidinophenylalanylpiperidinylamide (Ki 0.006 /tM; Hauptmann et al., 1985) are also excellent anticoagulants. These two inhibitors can double the PT and APTT at I /LM concentration with human plasma (Green et al., 1985; Hauptmann et al., 1985) . The potent Factor Xa inhibitor 1,2-bis-(5-amidinobenzofuran-2-yl)ethane also increases the APTT of human plasma 2-fold at 1.5 JM (Tidwell et al., 1980) . Two other types of compounds that have been tested recently as antithrombotic agents are p-amidinophenyl esters Pizzo et at., 1986) 7-fold at 44/#M in human plasma (Kam et al., 1988 ).
In conclusion, we have successfully synthesized the first arginylperfluoroalkanes. These compounds showed reasonably good inhibitory activity towards trypsin and several blood-coagulation enzymes. Although they only contained a single amino acid residue (arginine), these fluoroalkyl ketones already showed some selectivity towards the various coagulation enzymes. The potency and selectivity of these fluoroalkyl ketones would be expected to be increased by introducing systematic changes into the structure and by synthesizing longer peptide sequences. Bz-Arg-CF2CF3 and naphthoyl-Arg-CF3 also showed significant anticoagulant activity.
